COR vs HKPD
Cencora, Inc. and Cellyan Biotechnology Co. Ltd., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | COR | HKPD |
|---|---|---|
| Revenue | $321.3B | $20.3M |
| Net income | $1.6B | $-27,056 |
| Gross margin | 3.6% | 11.9% |
| Net margin | 0.5% | −0.1% |
| Return on equity | 144.3% | −0.6% |
| Diluted EPS | $7.96 | −$0.00 |
| Dividend / share | $2.20 | · |
| Payout ratio | 28.1% | · |
| Free cash flow | $3.2B | $499,298 |
| Equity | $1.5B | $5.0M |
| Net debt / equity | 2.19× | 0.23× |
| Current ratio | 0.90× | 2.99× |
| Revenue CAGR 5y | 11.1% | · |
| Profit CAGR 5y | · | · |
COR bills 15818.4× the revenue of HKPD, and HKPD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | COR | HKPD |
|---|---|---|
| FY2024 | $294.0B | $20.3M |
| FY2023 | $262.2B | $16.7M |
| FY2022 | $238.6B | $12.6M |
Bottom line
| Fiscal year | COR | HKPD |
|---|---|---|
| FY2024 | $1.5B | $-27,056 |
| FY2023 | $1.7B | $1.3M |
| FY2022 | $1.7B | $998,196 |
Standard deviation, each side
HKPD's net margin has been more volatile than COR's over the 3 comparable fiscal years — 3.8 percentage points of standard deviation against 0.1.
3 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between COR and HKPD over these 3 fiscal years — COR led in 1 and HKPD in 2.
3 of 19 comparable fiscal years — a year missing data on either side is not counted.